Therapies for actinic keratosis with a focus on cosmetic outcomes

Cutis

Volumn 96, Issue 3, 2015, Pages

  Lanoue, Julien ^a   Do, Timothy ^b   Goldenberg, Gary ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT;

CUTANEOUS DRUG ADMINISTRATION; HUMAN; KERATOSIS, ACTINIC; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; QUALITY OF LIFE;

ADMINISTRATION, CUTANEOUS; DERMATOLOGIC AGENTS; HUMANS; KERATOSIS, ACTINIC; PHOTOCHEMOTHERAPY; QUALITY OF LIFE;

EID: 84986634323     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Lebwohl M. Actinic keratosis: Epidemiology and progression to squamous cell carcinoma. Br J Dermatol. 2003; 149(suppl 66): 31-33.
2. Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol. 1995; 32: 95-98.
3. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000; 42(1, pt 2): 4-7.
4. Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol. 2006; 155: 9-22.
5. Anwar J, Wrone DA, Kimyai-Asadi A, et al. The development of actinic keratosis into invasive squamous cell carcinoma: Evidence and evolving classification schemes. Clin Dermatol. 2004; 22: 189-196.
6. Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009; 115: 2523-2530.
7. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000; 42(1, pt 2): 23-24.
8. Esmann S, Jemec GB. Management of actinic keratosis patients: A qualitative study. J Dermatolog Treat. 2007; 18: 53-58.
9. Weinstock MA, Lee KC, Chren MM, et al. Quality of life in the actinic neoplasia syndrome: The VA Topical Tretinoin Chemoprevention (VATTC) trial. J Am Acad Dermatol. 2009; 61: 207-215.
10. Berman B, Villa AM, Ramirez CC. Mechanisms of action of new treatment modalities for actinic keratosis. J Drugs Dermatol. 2006; 5: 167-173.
11. Askew DA, Mickan SM, Soyer HP. Effectiveness of 5-fluorouracil treatment for actinic keratosis: A systematic review of randomized controlled trials. Int J Dermatol. 2009; 46: 452-463.
12. Levy S, Furst K, Chern W. A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther. 2001; 23: 908-920.
13. Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis. 2002; 70: 335-359.
14. Sachs DL, Kang S, Hammerberg C, et al. Topical fluorouracil for actinic keratoses and photoaging: A clinical and molecular analysis. Arch Dermatol. 2009; 145: 659-666.
15. Hantash BM, Stewart DB, Cooper ZA, et al. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol. 2006; 142: 976-982.
16. Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol. 1995; 131: 176-181.
17. Monheit GD. The Jessner's + TCA peel: A medium-depth chemical peel. J Dermatol Surg Oncol. 1989; 15: 945-950.
18. Hemmi H, Kaisho T, Takeuchi O, et al. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002; 3: 196-200.
19. Adamson DJ, Frew D, Tatoud R, et al. Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling. Mol Pharmacol. 2002; 61: 7-12.
20. Alam CA, Seed MP, Willoughby DA. Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac in combination with hyaluronan in mice. J Pharm Pharmacol. 1995; 47: 407-411.
21. Lu X, Xie W, Reed D, et al. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc Natl Acad Sci USA. 1995; 92: 7961-7965.
22. Seed MP, Brown JR, Freemantle CN, et al. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res. 1997; 57: 1625-1629.
23. Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002; 146: 94-100.
24. Wolf JE, Taylor JR, Tschen E, et al. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001; 40: 709-713.
25. Nelson C, Rigel D, Smith S, et al. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol. 2004; 3: 401-407.
26. Pflugfelder A, Welter AK, Leiter U, et al. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: A trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol. 2012; 26: 48-53.
27. Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol. 2006; 5: 156-159.
28. Segatto MM, Dornelles SI, Silveira VB, et al. Comparative study of actinic keratosis treatment with 3% diclofenac sodium and 5% 5-fluorouracil. An Bras Dermatol. 2013; 88: 732-738.
29. Vidal D. Topical imiquimod: Mechanism of action and clinical applications. Mini Rev Med Chem. 2006; 6: 499-503.
30. Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: Systematic review and meta-analysis. J Invest Dermatol. 2006; 126: 1251-1255.
31. Caperton C, Berman B. Safety, efficacy, and patient acceptability of imiquimod for topical treatment of actinic keratoses. Clin Cosmet Investig Dermatol. 2011; 4: 35-40.
32. Swanson N, Smith CC, Kaur M, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Drugs Dermatol. 2014; 13: 166-169.
33. Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: A comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007; 157(suppl 2): 34-40.
34. Anderson L, Schmieder GJ, Werschler WP, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009; 60: 934-943.
35. Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: Plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004; 64: 2833-2839.
36. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012; 366: 1010-1019.
37. Lebwohl M, Shumack S, Stein-Gold L, et al. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013; 149: 666-670.
38. Augustin M, Tu JH, Knudsen KM, et al. Ingenol mebutate gel for actinic keratosis: The link between quality of life, treatment satisfaction, and clinical outcomes. J Am Acad Dermatol. 2015; 72: 816-821.
39. Kane-Maguire N, Moseley R, Cozzi S, et al. Modulation of fibroblast phenotype and extracellular matrix composition by ingenol mebutate may be associated with scar resolution and improved dermal cosmesis. J Am Acad Dermatol. 2012; 66: AB218.
40. Martin G, Swanson N. Clinical findings using ingenol mebutate gel to treat actinic keratoses. J Am Acad Dermatol. 2013; 68(1, suppl 1): S39-S48.
41. Feldman SR, Fleischer AB, Williford PM, et al. Destructive procedures are the standard of care for treatment of actinic keratoses. J Am Acad Dermatol. 1999; 40: 43-47.
42. Berlin JM. Current and emerging treatment strategies for the treatment of actinic keratosis. Clin Cosmet Investig Dermatol. 2010; 3: 119-126.
43. Coleman WP, Yarborough JM, Mandy SH. Dermabrasion for prophylaxis and treatment of actinic keratoses. Dermatol Surg. 1996; 22: 17-21.
44. Cooley JE, Casey DL, Kauffman CL. Manual resurfacing and trichloroacetic acid for the treatment of patients with widespread actinic damage. clinical and histologic observations. Dermatol Surg. 1997; 23: 373-379.
45. Goldberg LH, Kaplan B, Vergilis-Kalner I, et al. Liquid nitrogen: Temperature control in the treatment of actinic keratosis. Dermatol Surg. 2010; 36: 1956-1961.
46. Lubritz RR, Smolewski SA. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol. 1982; 7: 631-632.
47. Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004; 43: 687-692.
48. Zane C, Facchinetti E, Rossi MT, et al. Cryotherapy is preferable to ablative CO2 laser for the treatment of isolated actinic keratoses of the face and scalp: A randomized clinical trial. Br J Dermatol. 2014; 170: 1114-1121.
49. Trimas SJ, Ellis DA, Metz RD. The carbon dioxide laser. An alternative for the treatment of actinically damaged skin. Dermatol Surg. 1997; 23: 885-889.
50. Jiang SB, Levine VJ, Nehal KS, et al. Er: YAG laser for the treatment of actinic keratoses. Dermatol Surg. 2000; 26: 437-440.
51. Ostertag JU, Quaedvlieg PJ, Van der geer S, et al. A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses. Lasers Surg Med. 2006; 38: 731-739.
52. Iyer S, Friedli A, Bowes L, et al. Full face laser resurfacing: Therapy and prophylaxis for actinic keratoses and non-melanoma skin cancer. Lasers Surg Med. 2004; 34: 114-119.
53. Rubin MG. A peeler's thoughts on skin improvement with chemical peels and laser resurfacing. Clin Plast Surg. 1997; 24: 407-409.
54. Riggs K, Keller M, Humphreys TR. Ablative laser resurfacing: High-energy pulsed carbon dioxide and erbium: Yttrium-aluminum-garnet. Clin Dermatol. 2007; 25: 462-473.
55. Adrian RM. Pulsed carbon dioxide and long pulse 10-ms erbium-YAG laser resurfacing: A comparative clinical and histological study. J Cutan Laser Ther. 1999; 1: 197-202.
56. Weiss ET, Brauer JA, Anolik R, et al. 1927-nm fractional resurfacing of facial actinic keratoses: A promising new therapeutic option. J Am Acad Dermatol. 2013; 68: 98-102.
57. Manstein D, Herron GS, Sink RK, et al. Fractional photothermolysis: A new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med. 2004; 34: 426-438.
58. Katz TM, Goldberg LH, Marquez D, et al. Nonablative fractional photothermolysis for facial actinic keratoses: 6-month follow-up with histologic evaluation. J Am Acad Dermatol. 2011; 65: 349-356.
59. Prens SP, De Vries K, Neumann HA, et al. Non-ablative fractional resurfacing in combination with topical tretinoin cream as a field treatment modality for multiple actinic keratosis: A pilot study and a review of other field treatment modalities. J Dermatolog Treat. 2013; 24: 227-231.
60. Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: Nonablative, fractional, and ablative laser resurfacing. J Am Acad Dermatol. 2008; 58: 719-737.
61. Tannous Z. Fractional resurfacing. Clin Dermatol. 2007; 25: 480-486.
62. Gold MH. Continuing medical education article-skin treatment: Photodynamic therapy: Indications and treatment. Aesthet Surg J. 2008; 28: 545-552.
63. Juarranz A, Jaén P, Sanz-Rodríguez F, et al. Photodynamic therapy of cancer. basic principles and applications. Clin Transl Oncol. 2008; 10: 148-154.
64. Juzeniene A, Peng Q, Moan J. Milestones in the development of photodynamic therapy and fluorescence diagnosis. Photochem Photobiol Sci. 2007; 6: 1234-1245.
65. Moan J, Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol. 1991; 53: 549-553.
66. Gupta AK, Paquet M, Villanueva E, et al. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012; 12: CD004415.
67. Patel G, Armstrong AW, Eisen DB. Efficacy of photodynamic therapy vs other interventions in randomized clinical trials for the treatment of actinic keratoses: A systematic review and meta-analysis. JAMA Dermatol. 2014; 150: 1281-1288.
68. Kaufmann R, Spelman L, Weightman W, et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol. 2008; 158: 994-999.
69. Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: A prospective, randomized study. J Dermatolog Treat. 2003; 14: 99-106.
70. Morton C, Campbell S, Gupta G, et al. Intraindividual, right-left comparison of topical methyl aminolaevulinatephotodynamic therapy and cryotherapy in subjects with actinic keratoses: A multicentre, randomized controlled study. Br J Dermatol. 2006; 155: 1029-1036.
71. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: Results of a prospective randomized multicenter trial. J Am Acad Dermatol. 2003; 48: 227-232.
72. Zane C, Facchinetti E, Rossi MT, et al. A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp. Br J Dermatol. 2014; 170: 1143-1150.
73. Perrett CM, McGregor JM, Warwick J, et al. Treatment of post-transplant premalignant skin disease: A randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol. 2007; 156: 320-328.
74. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. J Am Acad Dermatol. 2002; 47: 258-262.
75. Scola N, Terras S, Georgas D, et al. A randomized, half-side comparative study of aminolaevulinate photodynamic therapy vs. CO(2) laser ablation in immunocompetent patients with multiple actinic keratoses. Br J Dermatol. 2012; 167: 1366-1373.
76. Willey A, Anderson RR, Sakamoto FH. Temperature-modulated photodynamic therapy for the treatment of actinic keratosis on the extremities: A pilot study. Dermatol Surg. 2014; 40: 1094-1102.
77. Pariser DM. Management of Actinic Keratoses: Treatment Selection and Optimizing Outcomes. Presented at: Winter Clinical Dermatology Conference Hawaii; January 18, 2015; Kaanapali, HI.
78. Dirschka T, Radny P, Dominicus R, et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol. 2013; 168: 825-836.
79. Choi SH, Kim KH, Song KH. Efficacy of ablative fractional laser-assisted photodynamic therapy with short-incubation time for the treatment of facial and scalp actinic keratosis: 12-month follow-up results of a randomized, prospective, comparative trial. J Eur Acad Dermatol Venereol. 2015; 29: 1598-1605.
80. Ko DY, Jeon SY, Kim KH, et al. Fractional erbium: YAG laser-assisted photodynamic therapy for facial actinic keratoses: A randomized, comparative, prospective study. J Eur Acad Dermatol Venereol. 2014; 28: 1529-1539.
81. Togsverd-Ho K, Haak CS, Thaysen-Petersen D, et al. Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: A randomized clinical trial. Br J Dermatol. 2012; 166: 1262-1269.
82. Torezan L, Chaves Y, Niwa A, et al. A pilot split-face study comparing conventional methyl aminolevulinatephotodynamic therapy (PDT) with microneedlingassisted PDT on actinically damaged skin. Dermatol Surg. 2013; 39: 1197-1201.